FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109378520> ?p ?o ?g. }

• W2109378520 endingPage "278" @default.
• W2109378520 startingPage "271" @default.
• W2109378520 abstract "An open-label, multicenter, randomized phase II trial was conducted from July 1, 2005 to March 29, 2011 to compare two protocols for treating children with frequently relapsing nephrotic syndrome using microemulsified cyclosporine.Ninety-three children with frequently relapsing nephrotic syndrome were randomly assigned to group A (n=46) or group B (n=47). In both groups, the 2-hour postdose cyclosporine level was monitored. For group A, the cyclosporine target was set to 600-700 ng/ml for the first 6 months and 450-550 ng/ml for the next 18 months; for group B, it was set to 450-550 ng/ml for the first 6 months and 300-400 ng/ml for the next 18 months. The primary end point was the sustained remission rate. At the end of the study, if there was no difference in safety profile between the two groups and the sustained remission rate in group A was superior to group B with a decision threshold of 8%, then the regimen for group A would be determined the better treatment.Eight children from an ineligible institution, where cyclosporine levels were not measured, were excluded from all analyses. At 24 months, the sustained remission rate was nonsignificantly higher in group A (n=43) than group B (n=42; 64.4% versus 50.0%; hazard ratio, 0.57; 95% confidence interval, 0.29 to 1.11; P=0.09), and the progression-free survival rate was significantly higher (88.1% versus 68.4%; hazard ratio, 0.33; 95% confidence interval, 0.12 to 0.94; P=0.03). The relapse rate was significantly lower in group A than group B (0.41 versus 0.95 times/person-year; hazard ratio, 0.43; 95% confidence interval, 0.19 to 0.84; P=0.02). The rate and severity of adverse events were similar in both treatment groups.The sustained remission rate was not significantly different between the two treatment groups, but the regimen with the higher 2-hour postdose cyclosporine level target improved progression-free survival and reduced the relapse rate." @default.
• W2109378520 created "2016-06-24" @default.
• W2109378520 creator A5003504692 @default.
• W2109378520 creator A5007720060 @default.
• W2109378520 creator A5014914035 @default.
• W2109378520 creator A5023674464 @default.
• W2109378520 creator A5024918216 @default.
• W2109378520 creator A5027021559 @default.
• W2109378520 creator A5033754308 @default.
• W2109378520 creator A5036822255 @default.
• W2109378520 creator A5057313515 @default.
• W2109378520 creator A5072056487 @default.
• W2109378520 creator A5073850979 @default.
• W2109378520 creator A5082872134 @default.
• W2109378520 creator A5084675851 @default.
• W2109378520 creator A5085246285 @default.
• W2109378520 creator A5088448746 @default.
• W2109378520 creator A5090555589 @default.
• W2109378520 creator A5090955736 @default.
• W2109378520 date "2014-02-01" @default.
• W2109378520 modified "2023-10-18" @default.
• W2109378520 title "Cyclosporine C2 Monitoring for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children" @default.
• W2109378520 cites W1962777145 @default.
• W2109378520 cites W1969595451 @default.
• W2109378520 cites W1970839485 @default.
• W2109378520 cites W1983883436 @default.
• W2109378520 cites W1986784482 @default.
• W2109378520 cites W1991050713 @default.
• W2109378520 cites W1991878257 @default.
• W2109378520 cites W1994069320 @default.
• W2109378520 cites W2002016277 @default.
• W2109378520 cites W2007364301 @default.
• W2109378520 cites W2015368836 @default.
• W2109378520 cites W2019698081 @default.
• W2109378520 cites W2026609854 @default.
• W2109378520 cites W2037828607 @default.
• W2109378520 cites W2065421753 @default.
• W2109378520 cites W2070457228 @default.
• W2109378520 cites W2072787516 @default.
• W2109378520 cites W2077272716 @default.
• W2109378520 cites W2080525944 @default.
• W2109378520 cites W2089711785 @default.
• W2109378520 cites W2115042832 @default.
• W2109378520 cites W2124807389 @default.
• W2109378520 cites W2127544448 @default.
• W2109378520 cites W2134468013 @default.
• W2109378520 cites W2141475336 @default.
• W2109378520 cites W2148715165 @default.
• W2109378520 cites W2156941604 @default.
• W2109378520 cites W2158765804 @default.
• W2109378520 cites W2329464731 @default.
• W2109378520 cites W4236065319 @default.
• W2109378520 doi "https://doi.org/10.2215/cjn.13071212" @default.
• W2109378520 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3913253" @default.
• W2109378520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24262503" @default.
• W2109378520 hasPublicationYear "2014" @default.
• W2109378520 type Work @default.
• W2109378520 sameAs 2109378520 @default.
• W2109378520 citedByCount "25" @default.
• W2109378520 countsByYear W21093785202014 @default.
• W2109378520 countsByYear W21093785202015 @default.
• W2109378520 countsByYear W21093785202016 @default.
• W2109378520 countsByYear W21093785202017 @default.
• W2109378520 countsByYear W21093785202018 @default.
• W2109378520 countsByYear W21093785202020 @default.
• W2109378520 countsByYear W21093785202021 @default.
• W2109378520 countsByYear W21093785202022 @default.
• W2109378520 countsByYear W21093785202023 @default.
• W2109378520 crossrefType "journal-article" @default.
• W2109378520 hasAuthorship W2109378520A5003504692 @default.
• W2109378520 hasAuthorship W2109378520A5007720060 @default.
• W2109378520 hasAuthorship W2109378520A5014914035 @default.
• W2109378520 hasAuthorship W2109378520A5023674464 @default.
• W2109378520 hasAuthorship W2109378520A5024918216 @default.
• W2109378520 hasAuthorship W2109378520A5027021559 @default.
• W2109378520 hasAuthorship W2109378520A5033754308 @default.
• W2109378520 hasAuthorship W2109378520A5036822255 @default.
• W2109378520 hasAuthorship W2109378520A5057313515 @default.
• W2109378520 hasAuthorship W2109378520A5072056487 @default.
• W2109378520 hasAuthorship W2109378520A5073850979 @default.
• W2109378520 hasAuthorship W2109378520A5082872134 @default.
• W2109378520 hasAuthorship W2109378520A5084675851 @default.
• W2109378520 hasAuthorship W2109378520A5085246285 @default.
• W2109378520 hasAuthorship W2109378520A5088448746 @default.
• W2109378520 hasAuthorship W2109378520A5090555589 @default.
• W2109378520 hasAuthorship W2109378520A5090955736 @default.
• W2109378520 hasBestOaLocation W21093785201 @default.
• W2109378520 hasConcept C126322002 @default.
• W2109378520 hasConcept C141071460 @default.
• W2109378520 hasConcept C168563851 @default.
• W2109378520 hasConcept C203092338 @default.
• W2109378520 hasConcept C207103383 @default.
• W2109378520 hasConcept C2777785397 @default.
• W2109378520 hasConcept C2778930706 @default.
• W2109378520 hasConcept C2781413609 @default.
• W2109378520 hasConcept C44249647 @default.
• W2109378520 hasConcept C71924100 @default.
• W2109378520 hasConcept C90924648 @default.

• next